Intellia Therapeutics, Inc. (NTLA) News

Intellia Therapeutics, Inc. (NTLA): $157.29

3.44 (+2.24%)

POWR Rating

Component Grades













Add NTLA to Watchlist
Sign Up

Industry: Biotech


of 506

in industry

Filter NTLA News Items

NTLA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NTLA News Highlights

  • For NTLA, its 30 day story count is now at 14.
  • Over the past 23 days, the trend for NTLA's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • The most mentioned tickers in articles about NTLA are VIVO, CAS and EDIT.

Latest NTLA News From Around the Web

Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.

Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients

The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate. NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms' Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML). Intellia plans to initiate patient screening by the end of 2021 for

Yahoo | September 16, 2021

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing com

Yahoo | September 16, 2021

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Chris Markoch on InvestorPlace | September 15, 2021

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Luke Lango on InvestorPlace | September 3, 2021

CRISPR-CAS 9 Technology Market Revolutionary CAGR +20% by 2028 with AstraZeneca, CRISPR Therapeutics, Editas Medicine, eGenesis, F. Hoffmann-La Roche, GenScript, Danaher, Intellia Therapeutics, Lonza, Merck KGaA, Intellia Therapeutics, Takara Bio, Thermo

CRISPR-CAS 9 Technology Market is projected to thrive $5 Bn at a CAGR +20% by the end of 2028. CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering

OpenPR | September 2, 2021

Pinduoduo (PINS) & Intellia Therapeutics (NTLA) technical analysis & Elliott Wave forecast [Video]

Intellia Therapeutics Inc. NTLA: Daily Elliott Wave Chart. The triangle is moving nicely as predicted last week. Id like to see one last leg down

FXStreet | August 31, 2021

Intellia Therapeutics to Present at September Healthcare Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following virtual healthcare investor conferences in September:

Intrado Digital Media | August 31, 2021

12 Best ARK Stocks To Invest In

In this article, we discuss the 12 best ARK stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best ARK Stocks to Invest In. As technology and growth stocks surged during the pandemic, ARK Investment Management and Cathie Wood became two of retail investors’ favorites over the previous […]

Yahoo | August 26, 2021

New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Yahoo | August 24, 2021

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Chris MacDonald on InvestorPlace | August 23, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 2.6661 seconds.